A comparison of letrozole regimens for ovulation induction in women with polycystic ovary syndrome.
F S Rep
; 5(2): 170-175, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38983726
ABSTRACT
Objective:
To determine the optimal letrozole regimen for ovulation induction (OI) in women with polycystic ovary syndrome (PCOS).Design:
Retrospective cohort study.Setting:
Single academic fertility clinic from 2015-2022. Patients A total of 189 OI cycles in 52 patients with PCOS.Interventions:
Patients were prescribed 1 of 4 letrozole regimens (group 1 2.5 mg for 5 days, group 2 2.5 mg for 10 days, group 3 5 mg for 5 days, and group 4 5 mg for 10 days). Main outcomemeasures:
The primary outcome was ovulation, and secondary outcomes included multifollicular development, and clinical pregnancy rate, which were analyzed with binary logistic regression. Kaplan-Meier cumulative response curves and a Cox proportional hazard regression model were used for time-dependent analyses.Results:
Mean age was 30.9 years (standard deviation [SD], 3.6) and body mass index was 32.1 kg/m2 (SD, 4.0). Group 2 (odds ratio [OR], 9.12; 95% confidence interval [CI], 1.92-43.25), group 3 (OR, 3.40; 95% CI, 1.57-7.37), and group 4 (OR, 5.94; 95% CI, 2.48-14.23) had improved ovulation rates after the starting regimen as compared with group 1. Cumulative ovulation rates exceeded 84% in all groups, yet those who received 5 mg and/or 10 days achieved ovulation significantly sooner. Multifollicular development was not increased in groups 2-4 as compared with group 1. Groups 2-4 also demonstrated improved time to pregnancy.Conclusions:
Ovulation rates are improved when starting with letrozole at 5 mg and/or a 10-day extended course as compared with the frequently-used 2.5 mg for 5 days. This may shorten time to ovulation and pregnancy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
F S Rep
Year:
2024
Document type:
Article